Small Molecule for Drug Overdose and Drug Toxicity is under clinical development by ResQ Pharma and currently in Phase III for Drug Toxicity. According to GlobalData, Phase III drugs for Drug Toxicity have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Small Molecule for Drug Overdose and Drug Toxicity’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Small Molecule for Drug Overdose and Drug Toxicity overview
Lipid rescue therapy (LRT) is under development for the treatment of local anesthetic systemic toxicity (LAST) and for the toxicity, poisoning, overdose of non-opioid drugs (NODO). LRT contains lipid emulsions administered as an intravenous infusion.
See Also:
ResQ Pharma overview
ResQ Pharma is a research and development company. The company is headquartered in Chicago, Illinois, the US
For a complete picture of Small Molecule for Drug Overdose and Drug Toxicity’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
